BioAge Q2 FY26 net loss widens to $26.1 million; R&D expenses rise to $24.37 million

• BioAge Labs posted a Q2 net loss of $26.1 million, worsening from $21.6 million a year earlier.
• R&D expenses rose to $24.4 million, up from $19.8 million, on higher BGE-102 costs tied to QUELL-CV initiation.
• Collaboration revenue was $2.4 million, in line with the year-earlier quarter.
• Cash, cash equivalents, marketable securities totaled $381.3 million as of June 30, with runway expected through 2029.
• First participant was dosed in QUELL-CV Phase 2; topline data are expected in H2 2026, with QUELL-DME planned mid-2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioage Labs Inc. published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein.